Anemia most significant adverse effect of HCV antiviral drugs boceprevir and telaprevir. This has been reported by researchers who studies the outcome in 1400 patients.
Triple therapy with one of these drugs plus ribavirin and pegylated interferon is now the standard of care for HCV genotype 1.
Of the 1,082 patients in the study taking telaprevir, 27 showed severe anemia, compared with five patients developing severe rash.
Among 344 patients on boceprevir, six developed severe anemia. [Read more...]